Morgan Stanley Maintains Overweight on Compass Pathways, Lowers Price Target to $16

Benzinga Newsdesk www.benzinga.com Negative 75.6%

Neg 75.6% Neu 0% Pos 0%

Morgan Stanley analyst Vikram Purohit maintains Compass Pathways (NASDAQ:CMPS) with a Overweight and lowers the price target from $18 to $16.